The Japanese government on March 7 announced new NHI prices for the FY2025 drug price revision, effective April 1. With…
BUSINESS
Kyowa Pharma Reveals Fudged Accelerated Stability Test of Mestinon
Kyowa Pharmaceutical Industry had conducted improper accelerated stability testing when filing for a partial change of its myasthenia gravis drug Mestinon (pyridostigmine bromide) back in 2009, it has been found out. The misconduct took place in a research center in…
To read the full story
Related Article
- Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President
January 29, 2025
- Kyowa Pharma Joins Medipal-JWP JV, Now Sister Firm to Nichi-Iko
March 6, 2024
- JGA Suspends Kyowa Pharma for 5 Years after GMP Violations
April 25, 2022
- Kyowa Pharma Hit by Biz Suspension over Manufacturing Flaws, Record Fabrications
March 29, 2022
- Kyowa Pharma to Face Biz Suspension Order over Manufacturing Flaws
March 23, 2022
- Kyowa to Resume Alfacalcidol Shipments in Mid-Sept.; MHLW Urges Priority for Patients without Alternative Therapies
September 2, 2021
BUSINESS
- GE Healthcare Fully Acquires Nihon Medi-Physics
April 1, 2025
- Ono Pairs Up with Reborna to Discover CNS Disease Drugs
April 1, 2025
- Chugai CEO’s Pay Tops 400 Million Yen in 2024: Securities Report
April 1, 2025
- Sawai to Pick Up Sumitomo Pharma’s Digital Healthcare Unit
April 1, 2025
- Santen’s Myopia Drug Recommended for European Approval
April 1, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…